LONDON – Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) reported positive results from its SLAB clinical trial in dogs and announced a collaboration with Acuitas Therapeutics, according to a press release statement issued today.
The SLAB trial, which enrolled 24 beagle dogs aged over 10 years, showed that all treatment groups demonstrated superior survival compared to the control group during the dosing period, with no adverse events observed. Follow-up observations taken three months after initial dosing in April confirmed the improvements had been maintained, with no adverse events recorded. The trial is expected to conclude at the end of July 2026.
A separate blinded trial, GF-1004, is assessing sarcopenia and healthspan-associated biomarkers over a 180-day monitoring period. A six-month efficacy assessment is expected in July 2026.
In April 2026, Genflow entered a technology collaboration with Acuitas Therapeutics, a Vancouver-based specialist in lipid nanoparticle delivery for mRNA therapeutics. Under the agreement, Genflow supplies its SIRT6 mRNA payload for Acuitas to formulate using its LNP platform. The collaboration is fully funded by Acuitas with no cash consideration payable by Genflow.
The company expanded its confidentiality agreements with additional animal health companies following the February SLAB interim results. Genflow has been invited to present SLAB study data at the Animal Longevity Summit in Toronto on October 1-2, 2026.
In April, Genflow’s international PCT application for “Variants of Sirtuin 6 for the Treatment of Muscular Diseases” was published, extending patent coverage into muscular disease indications including frailty syndrome and sarcopenia.
Gad Berdugo joined the Board as Independent Non-Executive Chairman in January 2026. He represented the company at the BIO International Convention in San Diego in June.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
